Many businesses promote unproven long-COVID treatments, researchers say
A new analysis finds that many clinics continue to promote unproven stem cell interventions as treatments for COVID-19 and long COVID. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 26, 2023 Category: Consumer Health News Source Type: news
Opening Our Eyes To Stem Cells For Stargardt's Macular Dystrophy
Stem cell therapies are being studied in clinical trials to treat retinitis pigmentosa, a genetic disorder that causes vision loss. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 26, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Stem Cell Transplants for Early MS: Who Benefits Most? Stem Cell Transplants for Early MS: Who Benefits Most?
Researchers are exploring HSCT as a rescue therapy in early-stage MS. But there ' s no consensus on best practices.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 25, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
- Resource consumption will be reduced by 50% to accelerate ALS development
- Plans underway for registrational Phase 3b U.S. clinical trial for NurOwn in ALS
NEW YORK, Oct. 24, 2023 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Thera... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, stem cell, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 24, 2023 Category: Pharmaceuticals Source Type: news
Food for Thought: A Recipe for Regenerating Nerves
Al dente asparagus stalks may hold the key to successful neural stem cell therapy for repairing injured axons. (Source: The Scientist)
Source: The Scientist - October 24, 2023 Category: Science Tags: News News & Opinion Source Type: news
First detailed U.S. scientific integrity draft policies get mixed responses
Keep working on it. That’s the reaction of U.S. science watchdog groups to the first attempts by federal health agencies to flesh out a promise by President Joe Biden to restore trust in government by ensuring that government scientists are free to do their jobs without political meddling.
One week after taking office in January 2021, Biden ordered
a review of agency policies on scientific integrity
, and 2 years later the White House
issued guidelines
for agencies to follow in revising existing policies. In July, the Department of Health and Human Services (HHS) was first across t...
Source: ScienceNOW - October 23, 2023 Category: Science Source Type: news
Differentiated Stem Cells Can Kickstart Fertility in Mice
Ovarian cells derived from stem cells restore hormones and cells needed to produce pups. (Source: The Scientist)
Source: The Scientist - October 23, 2023 Category: Science Tags: News News & Opinion Source Type: news
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
Path forward for ALS is a registrational Phase 3b U.S. clinical trial
Biologics License Application to be withdrawn without prejudice
Conference call and webcast at 8:30am ET today
NEW YORK, Oct. 18, 2023 -- (Healthcare Sales & Marketing Network) ... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, stem cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2023 Category: Pharmaceuticals Source Type: news
Gran who dropped 10lbs given four years to live after crushing diagnosis
Anne is urging people to join the stem cell register in the hopes of finding a donor. (Source: Daily Express - Health)
Source: Daily Express - Health - October 18, 2023 Category: Consumer Health News Source Type: news
Transplant joy for brave Emilia, five, thanks to stem cell donor in Germany
The donor's cells were flown to Oxford, then taken by blood bike to Birmingham so Emilia could receive the potentially life-saving infusion. (Source: Daily Express - Health)
Source: Daily Express - Health - October 15, 2023 Category: Consumer Health News Source Type: news
Overcoming Cancer Therapy Obstacles With Epitope Editing
Editing epitopes expressed on the surfaces of transplanted hematopoietic stem cells renders them resistant to AML treatments without affecting their critical functions. (Source: The Scientist)
Source: The Scientist - October 12, 2023 Category: Science Tags: News News & Opinion Source Type: news
New data for Roche ’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS ’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS controlled disease activity and progression over one year in Black and Hispanic / Latinx people with MSBasel, 12 October 2023 - Roch...
Source: Roche Media News - October 12, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS ’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS controlled disease activity and progression over one year in Black and Hispanic / Latinx people with MSBasel, 12 October 2023 - Roch...
Source: Roche Investor Update - October 12, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Media News - October 11, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Investor Update - October 11, 2023 Category: Pharmaceuticals Source Type: news
